Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05056688
Other study ID # AICUNI-YILDIRIM-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 30, 2021
Est. completion date September 28, 2022

Study information

Verified date October 2022
Source Agri Ibrahim Cecen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Aim: One of the cheapest, easiest and most effective ways to detect testicular cancer early is to resort to early detection screening methods associated with health beliefs about testicular cancer, and the second is to self-examine the testicles. In the country, there are a limited number of studies on the health beliefs and early diagnosis behaviors of young adult men for testicular cancer. For this reason, the study was conducted to determine the effect of online education given to young adults on testicular cancer health beliefs and behavior. Material and method: The research was conducted as a randomized controlled experimental study. The study population consisted of 768 individuals who applied to Family Health Centers affiliated to Agri Provincial Health Directorate between April 2021 and June 2022, and the sample of the research consisted of 90 individuals selected from the population using the improbable random sampling method. "Descriptive Feature Form", "Champion's Health Belief Model Scale in Testicular Cancer Screenings" were used to collect data. In the analysis of data; percentile distribution, chi-square, Fisher-Freeman-Halton Exact test, t-test in independent groups, Repeated Measures ANOVA Test, Friedman Test, One Way ANOVA test, Kruskall Wallis test, and post hoc analyzes (Bonferroni, Games Howell, Dunn) were used.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date September 28, 2022
Est. primary completion date September 28, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Being 18-35 years old, - Being literate, - Computer can be used, - Being able to access the Internet, - Not having a testicular diagnosis before, - Deciding to participate in the research. Exclusion Criteria: - Being outside the age range of 18-35, - To be diagnosed with testicular cancer before

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Testicular Model BSE/TSE Training Set
The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.

Locations

Country Name City State
Turkey Agri Ibrahim Cecen University Agri

Sponsors (1)

Lead Sponsor Collaborator
Agri Ibrahim Cecen University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Giving training to the experimental group for 6 weeks with an interval of 2 weeks. Individuals in the experimental and control group were evaluated with "Champion's Health Belief Model Scale in Testicular Cancer Screening". The effect of the training given to people in the online training group, which cannot be given to the control group, was changed at the end of 16 weeks with the mid-test "Champion's Health Belief Model Scale in Testicular Cancer Screening". A minimum of 26 points and a maximum of 130 points are obtained from Champion's Health Belief Model Scale in Testicular Cancer Screenings. The sub-dimensions of the scale are evaluated separately and there is no total score. Four monts
Primary Collection of the final test The mid-test for individuals in the experimental and control group was evaluated by the "Champion's Health Belief Model Scale in Testicular Cancer Screening". The effect of training given to those who could not be given to the control group in the online training group was replaced by the "Champion's Health Belief Model Scale in Testicular Cancer Screening" final test 3 months after training. A minimum of 26 points and a maximum of 130 points are obtained from Champion's Health Belief Model Scale in Testicular Cancer Screenings. The sub-dimensions of the scale are evaluated separately and there is no total score. Three monts
See also
  Status Clinical Trial Phase
Completed NCT00231582 - High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II Phase 2
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Terminated NCT02577172 - Testicular Cancer and Aerobic and Strength Training N/A
Completed NCT03403777 - Avelumab in Refractory Testicular Germ Cell Cancer. Phase 2
Completed NCT02890030 - The Platinum Study Comparison Group
Recruiting NCT05264337 - Lymphedema After Urologic Surgery
Active, not recruiting NCT03426865 - Role of Axumin PET Scan in Germ Cell Tumor
Completed NCT00001270 - Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma Phase 1
Completed NCT02459132 - High-Intensity Aerobic Interval Training in Testicular Cancer Survivors N/A
Completed NCT06309732 - GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT) Phase 2
Terminated NCT02499952 - Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Phase 2
Recruiting NCT02304575 - Quality of Life Among Testicular Cancer Survivors N/A
Withdrawn NCT02492360 - Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy N/A
Completed NCT04122430 - Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours
Recruiting NCT02229916 - Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
Completed NCT02161692 - Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors Phase 2
Completed NCT02966509 - Engagement of Patients With Advanced Cancer N/A
Recruiting NCT02341989 - Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer Phase 3
Terminated NCT05229900 - A Study of SGN-ALPV in Advanced Solid Tumors Phase 1
Completed NCT00123773 - Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence Phase 2